Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

Af­ter a cat­a­stroph­ic fail­ure in ac­ne that oblit­er­at­ed its stock just months ago, Der­mi­ra $DERM had some re­deem­ing news this morn­ing — the FDA has OK’ed its an­ti-sweat­ing drug gly­copy­rro­ni­um.

The med now goes un­der the brand name Qbrexza, and it’s a once-dai­ly, top­i­cal treat­ment for peo­ple with ex­ces­sive un­der­arm sweat­ing (al­so called pri­ma­ry ax­il­lary hy­per­hidro­sis). The treat­ment is ap­plied di­rect­ly to the skin, block­ing sweat gland ac­ti­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER